Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?
Or would you try to wait and get the steroids off first?
Answer from: Medical Oncologist at Academic Institution
In general immunotherapy should not be started if patients require predisone or the equivalent more than 10 mg a day.
Sign In
or
Register
to read more
2357
Related Questions
How have you used Hedgehog pathway inhibitors as neoadjuvant/adjuvant therapies?
How would a low tumor mutational burden (<10) influence your decision to offer neoadjuvant immunotherapy for cutaneous squamous cell carcinoma?
What is the current role of ctDNA in guiding the selection of adjuvant treatment for stage II-IIIA melanoma?
Would you recommend large-field radiation therapy to treat SCC of the skin with field cancerization (e.g., entire forearm, scalp) in elderly patients with CLL/immune compromise who have had mixed responses to cemiplimab?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
How does the latency from the original melanoma diagnosis affect your approach to neoadjuvant therapy in a patient with clinically detectable stage III nodal recurrence?
How would you approach management of a large, fungating squamous cell carcinoma of the auricle if surgical management is not desired by the patient?
Would you consider neoadjuvant immunotherapy prior to radiation for a locally advanced skin squamous cell carcinoma?
How do you manage new-onset vitiligo in a patient on immune checkpoint inhibitors?
How do you treat an isolated in-transit recurrence of melanoma without evidence of clinical nodal involvement in a patient with a history of previously resected primary melanoma?